Evolving Considerations in the Treatment of Metastatic Head and Neck Squamous Cell Carcinoma: A Closer Look at the Role of Immunotherapy.

Immunotherapy is a dramatic advance in the treatment of metastatic head and neck squamous cell carcinoma. Checkpoint inhibitors are improving survival in patients with late-stage disease and are moving into earlier lines of therapy.

Detalles Bibliográficos
Publicado en:Journal of Managed Care Medicine Vol. 22; no. 4; pp. 55 - 59
Autor principal: Burtness, Barbara
Formato: CEU pictorial tables/charts Journal Article
Publicado: National Association of Managed Care Physicians, Inc. 2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139925368&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 139925368
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10941525
        9084
      jtl: Journal of Managed Care Medicine
      issn: 10941525
      maglogo: N
    pubinfo:
      dt: 2019
      vid: 22
      iid: 4
      pid: 54351
      pub: National Association of Managed Care Physicians, Inc.
      place: Glen Allen, Virginia
    artinfo:
      ui:
        139925368
        139925368
        139925368
        139925368
      ppf: 55
      ppct: 4
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Evolving Considerations in the Treatment of Metastatic Head and Neck Squamous Cell Carcinoma: A Closer Look at the Role of Immunotherapy.
      aug:
        au: Burtness, Barbara
        affil: MD is a Professor of Medicine at the Yale School of Medicine and Co-Leader of the Developmental Therapeutics Program at the Yale Cancer Center in New Haven, CT
      sug:
        subj:
          Squamous Cell Carcinoma of Head and Neck Drug Therapy
          Neoplasm Metastasis
          Immunotherapy
          Education, Continuing (Credit)
          Antibodies, Monoclonal Therapeutic Use
          Squamous Cell Carcinoma of Head and Neck Prognosis
          Neoplasm Staging
      ab: Immunotherapy is a dramatic advance in the treatment of metastatic head and neck squamous cell carcinoma. Checkpoint inhibitors are improving survival in patients with late-stage disease and are moving into earlier lines of therapy.
      pubtype: Academic Journal
      doctype:
        CEU
        pictorial
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N